US Patent 9388191 Fused imidazole derivatives useful as IDO inhibitors

Patent 9388191 was granted and assigned to NewLink Genetics on July, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

NewLink Genetics

Current Assignee

NewLink Genetics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

9388191

Date of Patent

July 12, 2016

Patent Application Number

14794193

Date Filed

July 8, 2015

Patent Primary Examiner

‌

Erich A Leeser

Patent abstract

Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosuppression associated with an infectious disease.